Aldeyra Therapeutics Stock Price, News & Analysis (NASDAQ:ALDX)

$7.10 -0.15 (-2.07 %)
(As of 02/21/2018 08:30 AM ET)
Previous Close$7.25
Today's Range$7.05 - $7.34
52-Week Range$3.80 - $11.90
Volume24,400 shs
Average Volume100,571 shs
Market Capitalization$138.60 million
P/E Ratio-5.07
Dividend YieldN/A
Beta0.59

About Aldeyra Therapeutics (NASDAQ:ALDX)

Aldeyra Therapeutics logoAldeyra Therapeutics, Inc., formerly Aldexa Therapeutics, Inc., is a biotechnology company. The Company's principal activities include raising capital and research and development activities. The Company's segment is the identification and development of a treatment for diseases related to high levels of aldehydes. The Company is focused on the development of products for diseases caused by inflammation and inborn errors of metabolism that are caused by naturally occurring toxic and pro-inflammatory chemical species known as aldehydes. The Company has developed a series of aldehyde traps, molecules that are designed to sequester and allow for the degradation of aldehydes. The Company's aldehyde trap, NS2, is a product candidate that is under development for the treatment of allergic conjunctivitis and related rare allergic ocular diseases, noninfectious anterior uveitis, sjogren-larsson syndrome (SLS) and succinic semi-aldehyde dehydrogenase deficiency.

Receive ALDX News and Ratings via Email

Sign-up to receive the latest news and ratings for ALDX and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Bio Therapeutic Drugs
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:ALDX
CUSIPN/A
Phone781-761-4904

Debt

Debt-to-Equity Ratio0.02%
Current Ratio20.35%
Quick Ratio20.35%

Price-To-Earnings

Trailing P/E Ratio-5.07142857142857
Forward P/E Ratio-5.26
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book Value$1.72 per share
Price / Book4.13

Profitability

Trailing EPS($1.40)
Net Income$-18,690,000.00
Net MarginsN/A
Return on Equity-67.43%
Return on Assets-60.54%

Miscellaneous

Employees11
Outstanding Shares19,120,000

Aldeyra Therapeutics (NASDAQ:ALDX) Frequently Asked Questions

What is Aldeyra Therapeutics' stock symbol?

Aldeyra Therapeutics trades on the NASDAQ under the ticker symbol "ALDX."

How were Aldeyra Therapeutics' earnings last quarter?

Aldeyra Therapeutics Inc (NASDAQ:ALDX) announced its quarterly earnings data on Thursday, November, 9th. The biotechnology company reported ($0.32) EPS for the quarter, beating the Zacks' consensus estimate of ($0.41) by $0.09. View Aldeyra Therapeutics' Earnings History.

When will Aldeyra Therapeutics make its next earnings announcement?

Aldeyra Therapeutics is scheduled to release their next quarterly earnings announcement on Wednesday, March, 28th 2018. View Earnings Estimates for Aldeyra Therapeutics.

Where is Aldeyra Therapeutics' stock going? Where will Aldeyra Therapeutics' stock price be in 2018?

6 brokerages have issued 12 month price targets for Aldeyra Therapeutics' shares. Their predictions range from $13.00 to $27.00. On average, they anticipate Aldeyra Therapeutics' stock price to reach $18.33 in the next year. View Analyst Ratings for Aldeyra Therapeutics.

What are Wall Street analysts saying about Aldeyra Therapeutics stock?

Here are some recent quotes from research analysts about Aldeyra Therapeutics stock:

  • 1. According to Zacks Investment Research, "Aldeyra Therapeutics, Inc. is a biotechnology company. The company's products target immune-mediated, inflammatory, orphan, and other diseases. It is developing NS2, a compound that binds and traps free aldehydes. Aldeyra Therapeutics, Inc. is based in Burlington, Massachusetts. " (1/9/2018)
  • 2. Cowen Inc analysts commented, "On its 4Q call, ALDX announced the Feb start of the planned ADX-102 Ph2b allergic." (3/31/2017)

Who are some of Aldeyra Therapeutics' key competitors?

Who are Aldeyra Therapeutics' key executives?

Aldeyra Therapeutics' management team includes the folowing people:

  • Todd C. Brady M.D. Ph.D., President, Chief Executive Officer, Director (Age 46)
  • Stephen J. Tulipano CPA, Chief Financial Officer, Treasurer (Age 55)
  • Scott L Young, Chief Operating Officer (Age 51)
  • David J. Clark M.D., Chief Medical Officer
  • Ben Bronstein M.D., Director (Age 65)
  • Jesse I. Treu Ph.D., Director (Age 70)
  • Richard H. Douglas Ph.D., Independent Director (Age 64)
  • Martin J. Joyce, Independent Director (Age 61)
  • Gary M. Phillips M.D., Independent Director (Age 51)

Who owns Aldeyra Therapeutics stock?

Aldeyra Therapeutics' stock is owned by many different of retail and institutional investors. Top institutional shareholders include 683 CAPITAL MANAGEMENT, LLC Total Shares: 1,000,000 (5.20%), 683 Capital Management LLC (4.79%), Millennium Management LLC (3.74%), Mangrove Partners (0.86%), Geode Capital Management LLC (0.53%) and Renaissance Technologies LLC (0.32%). Company insiders that own Aldeyra Therapeutics stock include Life Sciences Maste Perceptive, Martin Joseph Joyce, Perceptive Advisors Llc, Stephen J Tulipano and Todd C Brady. View Institutional Ownership Trends for Aldeyra Therapeutics.

Who sold Aldeyra Therapeutics stock? Who is selling Aldeyra Therapeutics stock?

Aldeyra Therapeutics' stock was sold by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC. View Insider Buying and Selling for Aldeyra Therapeutics.

Who bought Aldeyra Therapeutics stock? Who is buying Aldeyra Therapeutics stock?

Aldeyra Therapeutics' stock was purchased by a variety of institutional investors in the last quarter, including Millennium Management LLC, Mangrove Partners, 683 Capital Management LLC, Geode Capital Management LLC and Woodstock Corp. Company insiders that have bought Aldeyra Therapeutics stock in the last two years include Life Sciences Maste Perceptive, Martin Joseph Joyce, Perceptive Advisors Llc, Stephen J Tulipano and Todd C Brady. View Insider Buying and Selling for Aldeyra Therapeutics.

How do I buy Aldeyra Therapeutics stock?

Shares of Aldeyra Therapeutics can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Aldeyra Therapeutics' stock price today?

One share of Aldeyra Therapeutics stock can currently be purchased for approximately $7.10.

How big of a company is Aldeyra Therapeutics?

Aldeyra Therapeutics has a market capitalization of $138.60 million. The biotechnology company earns $-18,690,000.00 in net income (profit) each year or ($1.40) on an earnings per share basis. Aldeyra Therapeutics employs 11 workers across the globe.

How can I contact Aldeyra Therapeutics?

Aldeyra Therapeutics' mailing address is 131 HARTWELL AVENUE SUITE 320, LEXINGTON MA, 02421. The biotechnology company can be reached via phone at 781-761-4904 or via email at [email protected]


MarketBeat Community Rating for Aldeyra Therapeutics (ALDX)

Community Ranking:  3.1 out of 5 (star star star)
Outperform Votes:  184 (Vote Outperform)
Underperform Votes:  114 (Vote Underperform)
Total Votes:  298
MarketBeat's community ratings are surveys of what our community members think about Aldeyra Therapeutics and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Aldeyra Therapeutics (NASDAQ:ALDX) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 3.003.003.003.00
Ratings Breakdown: 0 Sell Rating(s)
0 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $18.33$19.40$19.40$16.50
Price Target Upside: 152.87% upside205.51% upside205.51% upside270.79% upside

Aldeyra Therapeutics (NASDAQ:ALDX) Consensus Price Target History

Price Target History for Aldeyra Therapeutics (NASDAQ:ALDX)

Aldeyra Therapeutics (NASDAQ:ALDX) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
1/26/2018Seaport Global SecuritiesInitiated CoverageBuy$13.00MediumView Rating Details
10/24/2017Cantor FitzgeraldInitiated CoverageOverweight$22.00N/AView Rating Details
9/14/2017CowenReiterated RatingOutperform$9.00 -> $14.00HighView Rating Details
9/13/2017Canaccord GenuityReiterated RatingBuy -> Buy$12.00 -> $27.00MediumView Rating Details
8/9/2017HC WainwrightSet Price TargetBuy$18.00LowView Rating Details
5/31/2017Stifel NicolausReiterated RatingBuy$16.00MediumView Rating Details
2/29/2016Janney Montgomery ScottReiterated RatingBuyN/AView Rating Details
(Data available from 2/21/2016 forward)

Earnings

Aldeyra Therapeutics (NASDAQ:ALDX) Earnings History and Estimates Chart

Earnings by Quarter for Aldeyra Therapeutics (NASDAQ:ALDX)

Aldeyra Therapeutics (NASDAQ ALDX) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
3/28/2018($0.32)N/AView Earnings Details
11/9/2017Q3 2017($0.41)($0.32)ViewN/AView Earnings Details
8/8/2017Q2 2017($0.37)($0.35)ViewListenView Earnings Details
5/15/2017Q1 2017($0.33)($0.37)ViewN/AView Earnings Details
3/30/2017Q4 2016($0.66)($0.36)ViewN/AView Earnings Details
11/14/2016Q316($0.39)($0.38)ViewN/AView Earnings Details
8/10/2016Q216($0.44)($0.41)ViewListenView Earnings Details
5/9/2016Q116($0.50)($0.51)ViewN/AView Earnings Details
3/30/2016Q4 2015($0.30)($0.47)ViewN/AView Earnings Details
11/12/2015Q315($0.29)($0.35)ViewListenView Earnings Details
8/11/2015Q215($0.35)($0.27)ViewListenView Earnings Details
5/13/2015Q115($0.39)($0.32)ViewListenView Earnings Details
4/14/2015($0.39)($0.31)ViewN/AView Earnings Details
3/19/2015Q4 2014($0.39)($0.31)ViewN/AView Earnings Details
11/10/2014Q314($0.32)($0.36)ViewN/AView Earnings Details
8/4/2014Q214($0.53)($1.56)ViewN/AView Earnings Details
6/11/2014Q1 2014($4.00)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Estimates

Aldeyra Therapeutics (NASDAQ:ALDX) Earnings Estimates

Current Year EPS Consensus Estimate: $-1.35 EPS
Next Year EPS Consensus Estimate: $-1.39 EPS

Dividends

Dividend History for Aldeyra Therapeutics (NASDAQ:ALDX)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Aldeyra Therapeutics (NASDAQ ALDX) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 19.04%
Institutional Ownership Percentage: 48.65%
Insider Trades by Quarter for Aldeyra Therapeutics (NASDAQ:ALDX)
Institutional Ownership by Quarter for Aldeyra Therapeutics (NASDAQ:ALDX)

Aldeyra Therapeutics (NASDAQ ALDX) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
9/19/2017Life Sciences Maste PerceptiveMajor ShareholderBuy200,000$7.25$1,450,000.00View SEC Filing  
6/30/2017Life Sciences Maste PerceptiveMajor ShareholderBuy296,007$4.60$1,361,632.20View SEC Filing  
2/17/2017Martin Joseph JoyceDirectorBuy4,444$4.50$19,998.0017,944View SEC Filing  
2/17/2017Stephen J TulipanoCFOBuy3,333$4.50$14,998.503,333View SEC Filing  
2/17/2017Todd C BradyInsiderBuy22,223$4.50$100,003.5064,408View SEC Filing  
2/14/2017Perceptive Advisors LlcMajor ShareholderBuy893,025$4.50$4,018,612.50View SEC Filing  
5/26/2016Perceptive Advisors LlcMajor ShareholderBuy700,000$5.00$3,500,000.00View SEC Filing  
10/26/2015Perceptive Advisors LlcMajor ShareholderBuy50,000$6.46$323,000.00View SEC Filing  
10/22/2015Perceptive Advisors LlcMajor ShareholderBuy18,020$6.47$116,589.40View SEC Filing  
10/20/2015Perceptive Advisors LlcMajor ShareholderBuy37,145$6.39$237,356.55View SEC Filing  
8/7/2014Martin Joseph JoyceDirectorBuy1,000$3.95$3,950.00View SEC Filing  
8/6/2014C. Boyd ClarkeDirectorBuy3,000$3.69$11,070.00View SEC Filing  
5/7/2014C. Boyd ClarkeDirectorBuy12,500$8.00$100,000.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Aldeyra Therapeutics (NASDAQ ALDX) News Headlines

Source:
DateHeadline
Aldeyra Therapeutics Inc (ALDX) Receives Average Rating of "Buy" from AnalystsAldeyra Therapeutics Inc (ALDX) Receives Average Rating of "Buy" from Analysts
www.americanbankingnews.com - February 3 at 1:28 AM
Whats Next For Aldeyra Therapeutics? - Seeking AlphaWhat's Next For Aldeyra Therapeutics? - Seeking Alpha
seekingalpha.com - February 2 at 3:25 PM
Aldeyra Therapeutics Announces First Patient Enrolled in Dry Eye Disease Phase 2b Clinical Trial - PR Newswire (press release)Aldeyra Therapeutics Announces First Patient Enrolled in Dry Eye Disease Phase 2b Clinical Trial - PR Newswire (press release)
www.prnewswire.com - February 1 at 3:24 PM
Aldeyra Therapeutics Announces First Patient Enrolled in Dry Eye Disease Phase 2b Clinical TrialAldeyra Therapeutics Announces First Patient Enrolled in Dry Eye Disease Phase 2b Clinical Trial
finance.yahoo.com - January 30 at 3:23 PM
Aldeyra Therapeutics: Multiple Clinical Catalysts Make This A Buy - Seeking AlphaAldeyra Therapeutics: Multiple Clinical Catalysts Make This A Buy - Seeking Alpha
seekingalpha.com - January 27 at 3:26 PM
Aldeyra Therapeutics (ALDX) Coverage Initiated by Analysts at Seaport Global SecuritiesAldeyra Therapeutics (ALDX) Coverage Initiated by Analysts at Seaport Global Securities
www.americanbankingnews.com - January 26 at 9:12 PM
Aldeyra Therapeutics Inc (ALDX) Given Consensus Recommendation of "Buy" by BrokeragesAldeyra Therapeutics Inc (ALDX) Given Consensus Recommendation of "Buy" by Brokerages
www.americanbankingnews.com - January 9 at 1:40 AM
Aldeyra Therapeutics Inc (ALDX) Expected to Announce Earnings of -$0.33 Per ShareAldeyra Therapeutics Inc (ALDX) Expected to Announce Earnings of -$0.33 Per Share
www.americanbankingnews.com - January 5 at 9:14 PM
Aldeyra Therapeutics (ALDX) Upgraded to Buy by Zacks Investment ResearchAldeyra Therapeutics (ALDX) Upgraded to Buy by Zacks Investment Research
www.americanbankingnews.com - January 2 at 6:46 PM
Aldeyra Therapeutics (ALDX) Downgraded by Zacks Investment Research to HoldAldeyra Therapeutics (ALDX) Downgraded by Zacks Investment Research to Hold
www.americanbankingnews.com - December 26 at 5:33 PM
Biotech Stocks Research Reports Released on Repros Therapeutics, Aldeyra Therapeutics, Neothetics, and BioLine Rx - PR Newswire (press release)Biotech Stocks' Research Reports Released on Repros Therapeutics, Aldeyra Therapeutics, Neothetics, and BioLine Rx - PR Newswire (press release)
www.prnewswire.com - December 21 at 3:39 PM
Why Aldeyra Therapeutics Inc’s (NASDAQ:ALDX) CEO Pay Matters To YouWhy Aldeyra Therapeutics Inc’s (NASDAQ:ALDX) CEO Pay Matters To You
finance.yahoo.com - December 15 at 11:36 AM
Aldeyra Therapeutics Inc (ALDX) Given Average Rating of "Buy" by AnalystsAldeyra Therapeutics Inc (ALDX) Given Average Rating of "Buy" by Analysts
www.americanbankingnews.com - December 15 at 1:50 AM
Aldeyra Therapeutics (ALDX) Announces Data on Noninfectious ... - StreetInsider.comAldeyra Therapeutics (ALDX) Announces Data on Noninfectious ... - StreetInsider.com
www.streetinsider.com - November 29 at 3:34 PM
Aldeyra Therapeutics Presents Noninfectious Anterior Uveitis Phase 2 Clinical Trial Data to the American Uveitis Society Held at the American Academy of Ophthalmology 2017 Annual MeetingAldeyra Therapeutics Presents Noninfectious Anterior Uveitis Phase 2 Clinical Trial Data to the American Uveitis Society Held at the American Academy of Ophthalmology 2017 Annual Meeting
finance.yahoo.com - November 29 at 11:28 AM
Aldeyra Therapeutics, Inc. (ALDX) Given Consensus Rating of "Buy" by AnalystsAldeyra Therapeutics, Inc. (ALDX) Given Consensus Rating of "Buy" by Analysts
www.americanbankingnews.com - November 20 at 1:52 AM
FY2017 Earnings Estimate for Aldeyra Therapeutics, Inc. (ALDX) Issued By Cantor FitzgeraldFY2017 Earnings Estimate for Aldeyra Therapeutics, Inc. (ALDX) Issued By Cantor Fitzgerald
www.americanbankingnews.com - November 15 at 7:32 AM
Aldeyra Therapeutics, Inc. (ALDX) Stock Rating Upgraded by Zacks Investment ResearchAldeyra Therapeutics, Inc. (ALDX) Stock Rating Upgraded by Zacks Investment Research
www.americanbankingnews.com - November 14 at 8:28 PM
Aldeyra Therapeutics (ALDX) CEO Todd Brady on Q3 2017 Results - Earnings Call Transcript - Seeking AlphaAldeyra Therapeutics' (ALDX) CEO Todd Brady on Q3 2017 Results - Earnings Call Transcript - Seeking Alpha
seekingalpha.com - November 10 at 2:31 PM
Aldeyra Therapeutics, Inc. (ALDX) Releases Quarterly  Earnings Results, Beats Expectations By $0.09 EPSAldeyra Therapeutics, Inc. (ALDX) Releases Quarterly Earnings Results, Beats Expectations By $0.09 EPS
www.americanbankingnews.com - November 10 at 12:51 PM
Aldeyra Therapeutics Announces Third Quarter 2017 Financial ResultsAldeyra Therapeutics Announces Third Quarter 2017 Financial Results
finance.yahoo.com - November 9 at 4:44 PM
Does Aldeyra Therapeutics Inc’s (ALDX) Debt Level Pose A Serious Problem?Does Aldeyra Therapeutics Inc’s (ALDX) Debt Level Pose A Serious Problem?
finance.yahoo.com - November 9 at 4:44 PM
Aldeyra Therapeutics to Present at the Stifel 2017 Healthcare ConferenceAldeyra Therapeutics to Present at the Stifel 2017 Healthcare Conference
finance.yahoo.com - November 7 at 5:19 PM
Aldeyra Therapeutics, Inc. (ALDX) Scheduled to Post Earnings on MondayAldeyra Therapeutics, Inc. (ALDX) Scheduled to Post Earnings on Monday
www.americanbankingnews.com - November 6 at 5:22 AM
Aldeyra Therapeutics Schedules Webcast and Conference Call to Provide Third Quarter 2017 Financial ResultsAldeyra Therapeutics Schedules Webcast and Conference Call to Provide Third Quarter 2017 Financial Results
finance.yahoo.com - November 2 at 4:08 PM
Cantor Fitzgerald Weighs in on Aldeyra Therapeutics, Inc.s FY2017 Earnings (ALDX)Cantor Fitzgerald Weighs in on Aldeyra Therapeutics, Inc.'s FY2017 Earnings (ALDX)
www.americanbankingnews.com - October 27 at 9:44 AM
Aldeyra Therapeutics (ALDX) to Present Results on ADX-102 in Noninfectious Anterior Uveitis at AUSAldeyra Therapeutics (ALDX) to Present Results on ADX-102 in Noninfectious Anterior Uveitis at AUS
www.streetinsider.com - October 26 at 8:43 PM
Aldeyra Therapeutics, Inc. (ALDX) Given Consensus Rating of "Hold" by BrokeragesAldeyra Therapeutics, Inc. (ALDX) Given Consensus Rating of "Hold" by Brokerages
www.americanbankingnews.com - October 26 at 1:34 AM
Aldeyra Therapeutics (ALDX) to Present Results on ADX-102 in Noninfectious Anterior Uveitis at AUS - StreetInsider.comAldeyra Therapeutics (ALDX) to Present Results on ADX-102 in Noninfectious Anterior Uveitis at AUS - StreetInsider.com
www.streetinsider.com - October 25 at 9:36 PM
Aldeyra Therapeutics Announces Presentation of Results on the Efficacy of ADX-102 in Noninfectious Anterior Uveitis at the American Uveitis Society Held at the American Academy of Ophthalmology 2017 Annual MeetingAldeyra Therapeutics Announces Presentation of Results on the Efficacy of ADX-102 in Noninfectious Anterior Uveitis at the American Uveitis Society Held at the American Academy of Ophthalmology 2017 Annual Meeting
finance.yahoo.com - October 25 at 4:34 PM
UPDATE: Cantor Fitzgerald Starts Aldeyra Therapeutics (ALDX) at Overweight - StreetInsider.comUPDATE: Cantor Fitzgerald Starts Aldeyra Therapeutics (ALDX) at Overweight - StreetInsider.com
www.streetinsider.com - October 24 at 10:15 PM
Aldeyra Therapeutics (ALDX) Reports Datafor Aldehyde Sequestration as Potential Therapeutic Approach in Succinic ... - StreetInsider.comAldeyra Therapeutics (ALDX) Reports Datafor Aldehyde Sequestration as Potential Therapeutic Approach in Succinic ... - StreetInsider.com
www.streetinsider.com - October 24 at 5:06 PM
Aldeyra Therapeutics Presents Evidence for Aldehyde Sequestration as a Potential Therapeutic Approach in Succinic Semialdehyde Dehydrogenase Deficiency at the American Society of Human Genetics 2017 Annual MeetingAldeyra Therapeutics Presents Evidence for Aldehyde Sequestration as a Potential Therapeutic Approach in Succinic Semialdehyde Dehydrogenase Deficiency at the American Society of Human Genetics 2017 Annual Meeting
finance.yahoo.com - October 24 at 5:06 PM
Cantor Fitzgerald Initiates Coverage on Aldeyra Therapeutics, Inc. (ALDX)Cantor Fitzgerald Initiates Coverage on Aldeyra Therapeutics, Inc. (ALDX)
www.americanbankingnews.com - October 24 at 4:50 PM
Head-To-Head Analysis: Aldeyra Therapeutics (ALDX) vs. Its CompetitorsHead-To-Head Analysis: Aldeyra Therapeutics (ALDX) vs. Its Competitors
www.americanbankingnews.com - October 24 at 10:44 AM
Financial Review: Aldeyra Therapeutics (ALDX) and Its CompetitorsFinancial Review: Aldeyra Therapeutics (ALDX) and Its Competitors
www.americanbankingnews.com - October 18 at 2:24 PM
Aldeyra Therapeutics, Inc. (ALDX) Short Interest Down 45.3% in SeptemberAldeyra Therapeutics, Inc. (ALDX) Short Interest Down 45.3% in September
www.americanbankingnews.com - October 14 at 2:04 AM
Aldeyra Therapeutics, Inc. (ALDX) Downgraded to Sell at Zacks Investment ResearchAldeyra Therapeutics, Inc. (ALDX) Downgraded to Sell at Zacks Investment Research
www.americanbankingnews.com - October 10 at 8:56 PM
Aldeyra Therapeutics Announces New Data at 2017 Research & Development DayAldeyra Therapeutics Announces New Data at 2017 Research & Development Day
finance.yahoo.com - October 10 at 5:07 PM
Aldeyra Therapeutics, Inc. (ALDX) Expected to Announce Earnings of -$0.42 Per ShareAldeyra Therapeutics, Inc. (ALDX) Expected to Announce Earnings of -$0.42 Per Share
www.americanbankingnews.com - October 5 at 6:18 PM
Aldeyra Therapeutics (ALDX) Presents Novel Data on Efficacy of ADX-102 in Model of Succinic Semialdehyde ... - StreetInsider.comAldeyra Therapeutics (ALDX) Presents Novel Data on Efficacy of ADX-102 in Model of Succinic Semialdehyde ... - StreetInsider.com
www.streetinsider.com - October 5 at 1:07 PM
Aldeyra Therapeutics Announces Presentation of Novel Data on the Efficacy of ADX-102 in a Model of Succinic Semialdehyde Dehydrogenase Activity at the 2017 American Society of Human Genetics Annual MeetingAldeyra Therapeutics Announces Presentation of Novel Data on the Efficacy of ADX-102 in a Model of Succinic Semialdehyde Dehydrogenase Activity at the 2017 American Society of Human Genetics Annual Meeting
finance.yahoo.com - October 5 at 1:07 PM
Aldeyra Therapeutics Inc (ALDX): How Does It Impact Your Portfolio?Aldeyra Therapeutics Inc (ALDX): How Does It Impact Your Portfolio?
finance.yahoo.com - October 2 at 8:35 PM
/C O R R E C T I O N -- Aldeyra Therapeutics, Inc.//C O R R E C T I O N -- Aldeyra Therapeutics, Inc./
finance.yahoo.com - October 2 at 3:33 PM
Aldeyra Therapeutics, Inc. (ALDX) Receives Average Rating of "Buy" from BrokeragesAldeyra Therapeutics, Inc. (ALDX) Receives Average Rating of "Buy" from Brokerages
www.americanbankingnews.com - October 1 at 3:14 AM
Aldeyra Therapeutics, Inc. Announces Closing of Public Offering of Common Stock and Full Exercise of Option to ... - PR Newswire (press release)Aldeyra Therapeutics, Inc. Announces Closing of Public Offering of Common Stock and Full Exercise of Option to ... - PR Newswire (press release)
www.prnewswire.com - September 23 at 8:50 PM
Aldeyra Therapeutics, Inc. Announces Closing of Public Offering of Common Stock and Full Exercise of Option to Purchase Additional SharesAldeyra Therapeutics, Inc. Announces Closing of Public Offering of Common Stock and Full Exercise of Option to Purchase Additional Shares
finance.yahoo.com - September 22 at 2:47 PM
Life Sciences Maste Perceptive Purchases 200,000 Shares of Aldeyra Therapeutics, Inc. (ALDX) StockLife Sciences Maste Perceptive Purchases 200,000 Shares of Aldeyra Therapeutics, Inc. (ALDX) Stock
www.americanbankingnews.com - September 21 at 10:26 AM
Aldeyra Therapeutics to Present at the Annual Cantor Fitzgerald Global Healthcare ConferenceAldeyra Therapeutics to Present at the Annual Cantor Fitzgerald Global Healthcare Conference
finance.yahoo.com - September 20 at 3:39 PM
Mid-Morning Market Update: Markets Edge Higher; AutoZone Earnings Top Expectations - BenzingaMid-Morning Market Update: Markets Edge Higher; AutoZone Earnings Top Expectations - Benzinga
www.benzinga.com - September 19 at 3:44 PM

SEC Filings

Aldeyra Therapeutics (NASDAQ:ALDX) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Aldeyra Therapeutics (NASDAQ:ALDX) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Aldeyra Therapeutics (NASDAQ ALDX) Stock Chart for Wednesday, February, 21, 2018

Loading chart…

This page was last updated on 2/21/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.